SAN DIEGO--(EON: Enhanced Online News)--Pathway Genomics, a cutting-edge commercial-stage genomics company, announced today that Dr. Michael Nova, Chief Innovation Officer, will present and be a panelist at the 2017 CES Digital Health Conference in Las Vegas, Nevada. The Conference will be held January 4-8, 2017 at The Venetian Hotel.
“Healthcare is indeed now “Personalized and Audacious”
Dr. Nova will present at the following sessions:
- Consumer Health Data Goes to the Doctor on Wednesday January 4th from 11:30am-12:30pm in LVCC North Hall, N261
- The Audacity of Precision Medicine: Bona Fide, Fearless, Unchained on Friday January 6th from 1-1:30pm in Lando 4303, Level 4
“I am delighted to participate at CES Digital Health to discuss how Pathway’s OME™ Artificial Intelligence App and IBM Watson program can dramatically impact healthcare and the internet of things (IoT),” said Dr. Nova. “Healthcare is indeed now “Personalized and Audacious” and due to AI, Big Data and genetics, is dramatically changing for the user and physician.”
In other news, Pathway is also running a special New Year promotion during the month of January where patients can go online and order PathwayFit® test for only $199 through the Pathway Online Physician network with code MYPATHWAY.
About Pathway Genomics
Founded in 2008, Pathway Genomics offers digital healthcare and genetic testing. Based in San Diego, CA our CLIA and CAP accredited clinical laboratory provides physicians and their patients in 40+ countries with actionable and accurate precision healthcare information to improve health and wellness. The company’s program with IBM Watson is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individual’s health history.
Pathway believes in the power of “genetics first” to help make proactive, informed decisions about health and lifestyle. Our physician-ordered tests include assays for diet and weight loss, circulating tumor DNA (liquid biopsy), hereditary cancer, pharmacogenomics and carrier screening. For more about Pathway Genomics, visit www.pathway.com and follow us on Facebook, LinkedIn and Twitter.